Clinical trials: sponsored by ModernaTX, Inc.
SARS-CoV-2
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home.
- Trial name
- disCOVEries (NCT05367908)
- Where
- United States
- Volunteers
- 1,501 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
There are 2 parts to this study: a single ascending dose (single dose of mRNA-6231) part and a multiple ascending dose (repeat doses of mRNA-6231) part.
- Trial name
- NCT04916431
- Testing
- mRNA-6231
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
- Trial name
- NCT05366322
- Where
- United States
- Volunteers
- 124,879 people
- Sponsor
- ModernaTX, Inc.
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Methylmalonic Acidemia, Propionic Acidemia
"The MaP Study": Mapping the Patient Journey in MMA and PA
Longitudinal, exploratory, natural history study of patients with MMA due to mut deficiency and PA to characterize the changes in blood disease biomarkers over time and the frequency and severity of clinical events related to…
- Trial name
- NCT03484767
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 97 people
- Sponsor
- ModernaTX, Inc.
Prevention of Chikungunya Virus Infection
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects.
- Trial name
- NCT03829384
- Testing
- mRNA-1944
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infection
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1647 and mRNA-1443 cytomegalovirus vaccines in healthy adults
- Trial name
- NCT03382405
- Testing
- mRNA-1647, mRNA-1443
- Where
- 4 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-339851 in healthy subjects.
- Trial name
- NCT03345043
- Testing
- VAL-339851
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors
Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia
This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3704 in patients with methylmalonic acidemia/aciduria (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency between 1 to 18 years of age with elevated plasma…
- Trial name
- NCT03810690
- Testing
- mRNA-3704
- Sponsor
- ModernaTX, Inc.
Human Metapneumovirus and Human Parainfluenza Infection
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.
- Trial name
- NCT03392389
- Testing
- mRNA-1653
- Where
- 3 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.